GlassScriptPhysician profile
Robert J Buchanan
NPI 1134236102
$3,126.32
in general payments reported to CMS, 2019-2025
21 companies · $22.37 in 2025
The $22.37 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $108 · 2021: $1,277 · 2022: $448 · 2023: $362 · 2024: $388 · 2025: $22.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,538.32 | 2019-2024 | Infinity, Proclaim |
| Medtronic, INC. | $460.51 | 2021-2022 | |
| Nuvasive, INC. | $185.32 | 2019 | |
| Medtronic USA, INC. | $144.33 | 2019 | |
| Lundbeck LLC | $115.39 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $112.49 | 2022-2023 | Spravato |
| Neurocrine Biosciences, INC. | $80.42 | 2022-2024 | Ingrezza |
| Abbvie INC. | $77.68 | 2022-2024 | |
| Saluda Medical Americas, INC. | $73.25 | 2024 | Evoke |
| Boston Scientific Corporation | $60.88 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $47.86 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $43.80 | 2022-2024 | Amyvid, Kisunla |
| Acadia Pharmaceuticals INC | $42.76 | 2023-2025 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37.37 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $32.12 | 2022-2023 | Austedo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $17.97 | 2024 | Aduhelm |
| Takeda Pharmaceuticals U.S.A., INC. | $16.29 | 2023 | Trintellix |
| Neuropace, INC. | $15.24 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.62 | 2023 | Quviviq |
| Brainlab, INC. | $9.70 | 2023 | Image Guided Surgical Device |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.